Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

MICROBES AND INFECTION is a premier academic journal published by Elsevier, dedicated to the dynamic fields of immunology, infectious diseases, and microbiology. With a notable impact factor reflective of its high-quality research contributions, the journal is categorized in the Q2 quartile across these fields as of 2023. Based in France and operating since 1999, MICROBES AND INFECTION offers a platform for researchers, professionals, and students to disseminate and access cutting-edge findings that drive innovation and knowledge in microbial and infectious disease research. The journal is ranked impressively within the Scopus database, securing ranks such as #16 in Microbiology and #33 in Infectious Diseases, underscoring its high relevance in the scientific community. Subscribers to the journal can expect an array of articles, reviews, and original research, all designed to advance understanding and improve clinical practices in the fight against infectious agents. With its ongoing commitment to open access options, MICROBES AND INFECTION continues to foster global collaboration and information sharing in the pursuit of addressing pressing microbiological challenges.

Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi, published by BILIMSEL TIP YAYINEVI, is a leading journal dedicated to the field of infection diseases and clinical microbiology. With an ISSN of 1300-932X and an E-ISSN of 2602-2842, this journal has been an established Open Access platform since 1999, allowing researchers worldwide to access critical studies and advancements without barriers. The journal aims to disseminate high-quality research articles, reviews, and case studies that address emerging challenges in infection management and microbiological practices. By fostering a collaborative environment for professionals, researchers, and students alike, Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi plays a vital role in advancing knowledge and practices within the microbiological and clinical spheres. Its commitment to open access ensures that invaluable resources are widely available, supporting the growth and development of innovation in the medical field.

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.